NOVA-MRI - Novel Applications in 19F Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique that is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

Start date/End Date: 48 mesi –  1/02/2020 End date 31/01/2024

Totale  Finanziamento: € 4.051.634,04  

Budget quota UNICAM: € 261.499,68

Info at Cordis: https://cordis.europa.eu/project/id/859908

 

Acronimo: 
NOVA-MRI
Soggetto finaziatore: 
Commissione Europea – Programma H2020
Programma di Finanziamento e bando: 
Horizon 2020 - MSCA-ITN-ETN-2019 - Innovative Training Networks
Numero del progetto/Contratto: 
859908
Responsabile Scientifico: 
Prof.sa Piera Di Martino
ruolo Unicam: 
Partner
Partner: 
Nome: 
ACADEMISCH ZIEKENHUIS LEIDEN
Stato: 
Netherlands
Ruolo: 
Coordinator
Nome: 
HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
Stato: 
Germany
Ruolo: 
Partner
Nome: 
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Stato: 
Spain
Ruolo: 
Partner
Nome: 
STICHTING KATHOLIEKE UNIVERSITEIT
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
UNIVERSITAT DE BARCELONA
Stato: 
Spain
Ruolo: 
Partner
Nome: 
THE UNIVERSITY OF EDINBURGH
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
PERCUROS BV
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
MEDRES-MEDICAL RESEARCH GMBH
Stato: 
Germany
Ruolo: 
Partner
Nome: 
POLYPURE AS
Stato: 
Norway
Ruolo: 
Partner
Nome: 
CROZET MEDICAL GMBH
Stato: 
Germany
Ruolo: 
Partner
Tipo di finaziamento: 
Horizon 2020